Viva Biotech HoldingsFRA:VB0 +0.76%42 Return-on-Tangible-Asset is 4.31% as of Dec. 2025, which is 14% below its 10-year median of 5.03. GuruFocus rates FRA:VB0 with a GF Score™ of 42/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,413 Biotechnology companies, Viva Biotech Holdings ranks better than 87.19% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Viva Biotech Holdings's annualizedNet Income for the quarter that ended in Dec. 2025 was €23.8 Mil. Viva Biotech Holdings's average total tangible assets for the quarter that ended in Dec. 2025 was €551.7 Mil. Therefore, Viva Biotech Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 4.31%.
The historical rank and industry rank for Viva Biotech Holdings's Return-on-Tangible-Asset or its related term are showing as below:
FRA:VB0'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -10.16 Med: 5.03 Max: 51.05
Current: 4.87
During the past 10 years, Viva Biotech Holdings's highest Return-on-Tangible-Asset was 51.05%. The lowest was -10.16%. And the median was 5.03%.
FRA:VB0's Return-on-Tangible-Asset is ranked better than 87.19% of 1413
companies
in the Biotechnology industry
Industry Median: -35.77
vs FRA:VB0: 4.87
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Viva Biotech Holdings Return-on-Tangible-Asset Related Terms
Viva Biotech Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 4.31% mean?
Viva Biotech Holdings (FRA:VB0) has a Return-on-Tangible-Asset of 4.31% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Viva Biotech Holdings and its competitors. This is 14% below median its historical median of 5.03. According to the industry distribution chart, Viva Biotech Holdings ranks #181 out of 1413 companies in the Biotechnology industry, placing it in the top 12.8%.
Is Viva Biotech Holdings' Return-on-Tangible-Asset too high?
Viva Biotech Holdings' current Return-on-Tangible-Asset of 4.31% is 14% below median its 10-year median of 5.03. Based on the distribution chart, Viva Biotech Holdings ranks #181 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #181 out of 1413 companies for Return-on-Tangible-Asset. This places Viva Biotech Holdings in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Return-on-Tangible-Asset is 4.31%, which is 14% below median its own 10-year median of 5.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.13 — trading 47.8% above its estimated fair value. The current Return-on-Tangible-Asset is 4.31%, which is 14% below median its 10-year median of 5.03. Viva Biotech Holdings' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Return-on-Tangible-Asset is 4.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.13 is trading 47.8% above its estimated GF Value™ of €0.09.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Return-on-Tangible-Asset: 4.31% (14% below median its 10-year median of 5.03)
GF Value™: €0.09 vs. price of €0.13 (47.8% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
42GF Score
Get the complete analysis for FRA:VB0
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
